P53 expression, DNA ploidy and S-phase cell fraction in operable locally advanced non-small-cell lung cancer

British Journal of Cancer

Volumn 73, Issue 7, 1996, Pages 914-919

  Costa, A ^a   Silvestrini, R ^a   Mochen, C ^a   Lequaglie, C ^a   Boracchi, P ^b   Faranda, A ^a   Vessecchia, G ^a   Ravasi, G ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

DNA ploidy; Lung cancer; P53 expression; Prognosis; 3H thymidine labelling index

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN P53; TRITIUM;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE S PHASE; CELL FRACTIONATION; CONTROLLED STUDY; FLOW CYTOMETRY; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

EID: 0030005924     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.163     Document Type: Article

References (28)

1. ALAMA A, COSTANTINI M, REPETTO L, CONTE PF, SERRANO J, NICOLIN A, BARBIERI F, ARDIZZONI A AND BRUZZI P. (1990). Thymidine labelling index as prognostic factor in resected non-small cell lung cancer. Eur. J. Cancer, 26, 622-625.
2. AMADORI D, VOLPI A, CALLEA A, AMADUCCI L, MORGAGNI S, MAGNI E AND NANNI O. (1994). Clinical relevance of cell kinetics in breast cancer. Ann. NY Acad. Sci., 698, 186-192.
3. ANDERSEN PK, BORGEN O, GILL RD AND KEIDING N. (1992). Statistical Models based on Counting Processes. Springer-Verlag: New York.
4. CIBAS ES, MELAMED MR, ZAMAN MB AND KIMMEL M. (1989). The effect of tumour size and tumour cell DNA content on the survival of patients with stage I adenocarcinoma of the lung. Cancer, 63, 1552-1556.
5. COSTA A, FARANDA A, SCALMATI A, QUAGLIUOLO V, COLELLA G, PONZ DE LEON M AND SILVESTRINI R (1992). Autoradiographic and flow-cytometric assessment of cell proliferation in primary colorectal cancer: relationship to DNA ploidy and clinico-pathological features. Int. J. Cancer, 50, 719-723.
6. COSTA A, MARASCA R, VALENTINIS B, SAVARINO M, FARANDA A, SILVESTRINI R AND TORELLI G. (1995). P53 gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancers. J. Pathol., 176, 45-53.
7. EBINA M, STEINBERG SM, MULSHINE JL AND LINNOILA RI. (1994). Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res., 54, 2496-2503.
8. FILDERMAN AE, SILVESTRINI GA, GATSONIS C, LUTHRINGER DJ, HONIG J AND FLYNN SD (1992). Prognostic significance of tumour proliferative fraction and DNA content in stage I non-small cell lung cancer. Am. Rev. Respir. Dis., 146, 707-710.
9. ISOBE H, MIYAMOTO H, SHIMIZU T, HANEDA H, HASHIMOTO M, INOUE K, MIZUNO S AND KAWAKAMI Y. (1990). Prognostic and therapeutic significance of the flow cytometric nuclear DNA content in non-small-cell lung cancer. Cancer, 65, 1391-1395.
10. KERR KM, ROBERTSON AMG AND LAMB D. (1983). In vitro thymidine labelling of human pulmonary neoplasms. Br. J. Cancer, 47, 245-252.
11. LE CHEVALIER T, ARRIGADA R, QUIOX E, RUFFIE P, MARTIN M, TARAYRE M, LACOMBE-TERRIER MJ, DAUILLARD JY AND LAPLANCHE A. (1991). Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: first analysis of a randomised trial in 353 patients. J. Natl. Cancer Inst., 83, 417-423.
12. MCLAREN R, KUZU I, DUNNILL M, HARRIS A, LANE D AND GATTER KC. (1992). The relationship of p53 immunostaining to survival in carcinoma of the lung. Br. J. Cancer, 66, 735-738.
13. MARINO P, PAMPALLONA S, PREATONI A, CANTONI A AND INVERNIZZI F. (1994). Chemotherapy versus supportive care in advanced non-small cell lung cancer. Results of a meta-analysis of the literature. Chest, 106, 861-865.
14. MARTINI N AND FLEHINGER BJ. (1987). The role of surgery in N2 lung cancer. Surg. Clin. North. Am., 67, 1037-1049.
15. MIYAMOTO H, HARADA M, ISOBE HD, AKITA HD, HANEDA H, YAMAGUCHI E, KUZUMAKI N AND KAWAKAMI Y (1991). Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer. Cancer Res., 51, 6346-6350.
16. MØRKVE O, HALVORSEN OJ, SKJAERVEN R, STANGELAND L, GULSVIK A AND LAERUM OD. (1993). Prognostic significance of p53 protein expression and DNA ploidy expression and DNA ploidy in surgically treated non-small cell lung carcinomas. Anticancer Res., 13, 571-578.
17. MOUNTAIN CF. (1986). A new international staging system for lung cancer. Chest, 89 (suppl.), 225s-33s.
18. NARUKE T, GOYA T, TSUCHIYA R AND SUEMASU K. (1988). The importance of surgery to non-small-cell carcinoma of lung with mediastinal lymph node mestastasis. Ann. Thorac. Surg., 46, 603-610.
19. PARADISO A, MANGIA A, BARLETTA A, CATINO AM, GIANNUZZI A, SCHITTULLI F, RADOGNA N, LONGO S, PALMIERI D, MARZULLO F, NATALE C, TARDIO B AND DE LENA M. (1993). Randomised clinical trial of adjuvant chemotherapy in patients with node-negative, fast-proliferating breast cancer. Drugs, 45 (suppl. 2), 68-74.
20. PASSLICK B, IZBICKI JR, RIETHMÜLLER G AND PANTEL K. (1994). P53 in non-small-cell lung cancer. J. Natl. Cancer Inst., 86, 801-803.
21. QUINLAN DC, DAVIDSON AG, SUMMERS CL, WARDEN HE AND DOSHI HM. (1992). Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res., 52, 4828-4831.
22. SCAGLIOTTI GV, MICELA M, GUBETTA L, LEONARDO E, CAPPIA S, BORASIO P AND POZZI E. (1993). Prognostic significance of Ki67 labelling in resected non small cell lung cancer. Eur. J. Cancer, 29A, 363-365.
23. SILVESTRINI R, MUSCOLINO G, COSTA A, LEQUAGLIE C, VENERONI S, MEZZANOTTE G AND RAVASI G. (1991). Could cell kinetics be a predictor of prognosis in non-small cell lung cancer? Lung Cancer, 7, 165-170.
24. SILVESTRINI R, BENINI E, DAIDONE MG, VENERONI S, BORACCHI P, CAPPELLETTI V, DI FRONZO G AND VERONESI U. (1993). P53 as an independent prognostic marker in lymph node-negative breast cancer patients. J. Natl. Cancer Inst., 85, 965-970.
25. SILVESTRINI R. (1994). Cell kinetics: prognostic and therapeutic implications in human tumours. Cell Prolif., 27, 579-596.
26. SILVESTRINI R, RAO S, BENINI E, DAIDONE MG AND PILOTTI S. (1995). Immunohistochemical detection of p53 in clinical breast cancers: a look at methodologic approaches. J. Natl. Cancer Inst. (in press).
27. TUNGEKAR MF, GAFFER KC, DUNHILL MS AND MASON DY. (1991). Ki-67 immunostaining and survival in operable lung cancer. Histopathology, 19, 545-550.
28. VOLM M, DRINGS P, MATTERN J, SONKA J, VOGT-MOYKOPF I AND WAYSS K. (1985). Prognostic significance of DNA patterns and resistance-predictive tests in non-small cell lung carcinoma. Cancer, 56, 1396-1403.